How much does midostaurin targeted drug cost?

Midostaurin, a tyrosine kinase inhibitor, has played an increasingly important role in the treatment of hematological malignancies in recent years. This drug has the ability to selectively inhibit the activating mutation of the KIT gene. In the treatment of severe patients, about 60% of patients can significantly improve their condition.

Especially in the treatment of acute myeloid leukemia (AML), midostaurin has shown its unique efficacy. As the first new drug for AML in 25 years, it is not only the first targeted drug to be used in combination with chemotherapy, but also has shown impressive results in clinical trials. In an international multi-center phase 3 clinical trial involving 3277 AML patients, 717 FLT3+ patients received midostaurin combined with chemotherapy. The results showed that compared with patients who received chemotherapy alone, the median overall survival of the combined treatment group was significantly longer, reaching 74.7 months, while the median overall survival of the control group was only 25.6 months. In addition, the 4-year overall survival rate of the combination treatment group was also significantly higher than that of the control group.

In addition toAML, midostaurin has also achieved impressive results in the treatment of systemic mastocytosis (SM) and its related hematological tumors. It can effectively inhibit the abnormal proliferation of mast cells, reduce patients' symptoms, and improve their quality of life.

Midostaurin has not yet entered the domestic market, and patients are temporarily unable to purchase this original drug through domestic hospitals or pharmacies. It is produced by the Swiss pharmaceutical company Novartis and each box contains 112 25mg tablets. Market prices in different countries fluctuate. The price in the European market is as high as about 120,000 yuan, while in the Turkish market it is slightly lower, about 80,000 yuan. It is worth mentioning that in the Indian market, the price of midostaurin is more affordable, only about 17,000 yuan. At the same time, the Indian company BDR also launched a generic version of midostaurin at a more affordable price, only about 9,000 yuan per box. For any questions or concerns about midostaurin, patients are advised to consult overseas medical consultants in a timely manner to obtain professional answers.

In general, with its unique mechanism and significant efficacy, midostaurin has occupied a place in the treatment of hematological malignancies, bringing new hope to many patients.